Yervoy (ipilimumab) is a medication used to treat advanced melanoma. It is an immunotherapy drug that works by activating the immune system to attack cancer cells. However, there is limited information on whether the dosage of Yervoy should be different for obese patients.

According to the drug patent information [1], the recommended dosage of Yervoy is 3 mg/kg administered intravenously over 90 minutes every three weeks for a total of four doses. However, this information does not specify whether the dosage should be adjusted for obese patients.

A recent study published in JAMA Oncology [3] investigated the impact of obesity on the efficacy of immunotherapy drugs, including Yervoy. The study found that obese patients had a lower response rate to immunotherapy drugs compared to non-obese patients. However, the study did not provide information on whether the dosage of Yervoy should be adjusted for obese patients.

Another study published in the National Library of Medicine [2] reported that there is no clear evidence to suggest that the dosage of Yervoy should be adjusted for obese patients. However, the study noted that obese patients may have a higher risk of experiencing side effects from the medication, such as diarrhea and colitis.

In conclusion, while there is limited information on whether the dosage of Yervoy should be different for obese patients, current evidence suggests that the recommended dosage of 3 mg/kg should be used. However, obese patients may have a higher risk of experiencing side effects from the medication. As with any medication, it is important for healthcare providers to carefully monitor patients for any adverse effects and adjust the dosage as needed.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134762/
[3] https://jamanetwork.com/journals/jamaoncology/fullarticle/2799188